SLC6A3 and Parkinson disease: Additionally, Pagano et al.'s study showed that PD patients with T2DM exhibited lower striatal dopamine transporter binding on [123I]FP-CIT SPECT imaging compared to Parkinson's patients without DM (Pagano et al. 2018).